Actively Recruiting
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Led by ImmunityBio, Inc. · Updated on 2026-05-04
20
Participants Needed
2
Research Sites
132 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
CONDITIONS
Official Title
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years
- Able to understand and sign informed consent according to ethics guidelines
- Histologically or flow cytometry confirmed B-cell Non-Hodgkin Lymphoma excluding primary CNS lymphoma, chronic lymphocytic leukemia, and Burkitt lymphoma
- Completed at least two lines of cytotoxic chemotherapy
- Previously treated with rituximab or another anti-CD20 antibody
- Measurable disease by Lugano classification within 8 weeks before consent
- ECOG performance status of 0 to 1
- Willingness to comply with study procedures
- Ability to attend study visits and follow-up
- Agreement to use effective contraception during and for 30 days after the study for females of childbearing potential and nonsterile males
You will not qualify if you...
- Diagnosis of primary CNS lymphoma, chronic lymphocytic leukemia, Burkitt, or Burkitt-like lymphoma
- Allergy or hypersensitivity to study drugs or components including sulfa-containing medications
- Inadequate organ function shown by low ANC, low platelet count, elevated bilirubin (except Gilbert's syndrome), elevated liver enzymes, high alkaline phosphatase, or high serum creatinine
- Serious uncontrolled diseases that increase risk for treatment complications
- History or active significant autoimmune disease requiring steroids over 20 mg prednisone daily
- History of allogeneic stem-cell transplant requiring ongoing graft versus host disease therapy
- Anti-CD20 antibody treatment within 2 weeks prior to cell infusion
- History of organ transplant requiring immunosuppression
- Post solid organ transplant with high-grade lymphomas or leukemias
- CNS metastases or nonmalignant CNS diseases
- Active inflammatory bowel disease
- Uncontrolled hypertension or significant cardiovascular or cerebrovascular disease within 6 months
- Chronic daily systemic corticosteroid use over 20 mg prednisone excluding inhaled steroids
- Use of medications known to interact adversely with study drugs
- Positive tuberculosis test
- HIV with low CD4 count and detectable viral load
- Active hepatitis B infection
- Concurrent active cancer other than certain skin cancers
- Inability or unwillingness to comply with protocol
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Dr. Jackie Thomson Inc
Johannesburg, South Africa, 2193
Actively Recruiting
2
Albert Cellular Therapy
Pretoria, South Africa, 0044
Actively Recruiting
Research Team
A
Atessa Kiani, MD
CONTACT
M
Mark Nelson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here